Vancouver, British Columbia - TheNewswire – October 14, 2021 – Blackhawk Growth Corp. (CSE:BLR) (CSE:BLR) (Frankfurt:0JJ) (the "Company" or "Blackhawk") is pleased to announce that Dr. Lahiru Russell from Digital Mind Technology has been appointed as a medical advisor to Blackhawk.
Dr. Russell, with over 10 years of experience in clinical trials and research in psycho-oncology, is developing a platform for mindfulness-based interventions to promote self-regulation of emotions and thoughts to reduce negative mental health conditions.
Dr. Russell has transferred all her relevant intellectual property to Digital Mind Technology including proven clinical tools (developed from clinical research with 69 patients diagnosed with advanced stage Melanoma), for actively engaging and treating patients to help cope with the negative mental health outcomes of their illness. MindBio currently has a commercialization agreement with Digital Mind Technology.
In addition, MindBio is planning to implement Google Cloud's "Health Care Solutions" for its international clinical trials to better manage clinical trials and analysis of data for drug development.
Google has developed cloud solutions that can help accelerate drug development and clinical trials to bring therapies to patients faster. With the Food and Drug Administration's (FDA) MyStudies Application integration, the Google Cloud uses mobile tools to recruit, enroll, and engage with patients, collecting data directly from participants in a regulatory-compliant manner.
MindBio's partner, Digital Mind Technology, will provide consulting services to MindBio on best practices and implementation of the Google health solution. Digital Mind Technology, run by Dr. Lahiru Russel, has used Google's health solutions extensively in her clinical trials and PhD. The intellectual property and knowledge of these trials have been transferred to Digital Mind where she is now building a platform for mindfulness interventions to promote self-regulation of emotions and thoughts that lead to a reduction in mental health conditions.
"Dr. Russell is a welcome addition to our team" said Frederick Pels, CEO of Blackhawk Growth Corp. "Her experience will be a relied upon asset for MindBio, Leichtmind and Trip Pharma. I look forward to updating shareholders with our progress as we continue to grow our life science initiative."
About Blackhawk Growth
Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, and MindBio Therapeutics. Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.
The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A
Please join the conversation on our Blackhawk group supporter's telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.
For further information please contact:
Frederick Pels, Chief Executive Officer
(403)-991-7737
fred@blackhawkgrowth.com
Cautionary Note Regarding Forward-Looking Statement
All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company's public filings under the Company's SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.
Copyright (c) 2021 TheNewswire - All rights reserved.
温哥華,不列顛哥倫比亞省-The Newswire(新聞通訊社)-2021年10月14日-黑鷹增長公司(CSE:BLR)(CSE:BLR)(法蘭克福:0JJ)(“公司“或”黑鷹“)很高興地宣佈,拉希魯博士來自Digital Mind Technology的羅素已被任命為黑鷹的醫療顧問。
羅素博士在心理腫瘤學的臨牀試驗和研究方面有10多年的經驗,他正在開發一個基於正念的幹預平臺,以促進情緒和思想的自我調節,以減少負面的心理健康狀況。
羅素博士已經將她所有相關的知識產權轉讓給數字心智技術包括經過驗證的臨牀工具(從69名被診斷為晚期黑色素瘤的患者的臨牀研究中開發),用於積極吸引和治療患者,以幫助應對其疾病帶來的負面心理健康後果。MindBio目前與數字心智技術.
此外,MindBio還計劃實施Google Cloud的醫療保健解決方案其國際臨牀試驗將更好地管理藥物開發的臨牀試驗和數據分析。
谷歌已經開發了雲解決方案,可以幫助加快藥物開發和臨牀試驗,以更快地將療法帶給患者。美國食品和藥物管理局(FDA)MyStudies應用程序通過整合,Google Cloud使用移動工具招募、登記和接觸患者,以符合法規的方式直接從參與者那裏收集數據。
MindBio的合作伙伴數字思維技術公司(Digital Mind Technology)將向MindBio提供谷歌健康解決方案的最佳實踐和實施方面的諮詢服務。由拉希魯·羅素(Lahiru Russel)博士運營的數字心靈技術公司(Digital Mind Technology)在她的臨牀試驗和博士學位中廣泛使用了谷歌的健康解決方案。這些試驗的知識產權和知識已經轉移到了Digital Mind,她現在正在那裏建立一個正念幹預的平臺,以促進對導致精神健康狀況下降的情緒和思想的自我調節。
BlackHawk Growth Corp.首席執行官弗雷德裏克·佩爾斯(Frederick Pels)表示:“拉塞爾博士是我們團隊的一位受歡迎的新成員。”她的經驗將是MindBio、LeichtMind和Trip Pharma的可靠資產。我期待着在我們繼續發展我們的生命科學計劃的同時,向股東通報我們的最新進展。“
關於黑鷹成長
黑鷹是一家投資控股公司,希望通過收購和發展高增長公司為其股東創造實質性價值。該公司將投資重點放在加拿大和美國的健康、大麻和大麻二醇行業。它的公司組合包括SAC製藥公司、LeichtMind診所、Noble Hemp公司、Spaced Food公司、NuWave食品公司和MindBio治療公司。黑鷹繼續將其投資轉化為現金流,並正在以超乎尋常的速度增長。
該公司勤奮地通過公司Youtube官方頻道https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A的視頻發佈最新消息
請在https://t.me/Blackhawkgrowthcorp上加入我們的黑鷹團體支持者電報羣的對話並在線訪問我們的網站Https://www.blackhawkgrowth.com.
如需更多信息,請聯繫:
首席執行官弗雷德裏克·佩爾斯(Frederick Pels)
(403)-991-7737
弗雷德@Blackhawkgrowth.com
關於前瞻性陳述的注意事項
本新聞稿中的所有聲明,除歷史事實的陳述是適用證券法所指的與公司有關的“前瞻性信息”,包括與MindBio治療有限公司的交易和未來業務有關的信息。公司提供前瞻性陳述的目的是傳達有關當前對未來的預期和計劃的信息,請讀者注意,此類陳述可能不適用於其他目的。就其性質而言,這些信息受固有風險和不確定性的影響,這些風險和不確定性可能是一般性或具體性的,並可能導致預期、預測或結論被證明不準確,假設可能不正確,目標、戰略目標和優先事項無法實現。這些風險和不確定因素包括但不限於公司在www.sedar.com的SEDAR簡介中確認並在公司的公開申報文件中報告的風險和不確定性。儘管公司試圖找出可能導致實際行動、事件或結果與前瞻性信息中描述的大不相同的重要因素,但也可能有其他因素導致行動、事件或結果與預期、估計或預期的不同。不能保證這些信息將被證明是準確的,因為實際結果和未來事件可能與此類聲明中預期的大不相同。除非法律要求,否則公司不會因為新信息、未來事件或其他原因而更新或修改任何前瞻性信息,也不承擔任何義務。
版權所有(C)2021 TheNewswire-保留所有權利。